Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q15427
UPID:
SF3B4_HUMAN
Alternative names:
Pre-mRNA-splicing factor SF3b 49 kDa subunit; Spliceosome-associated protein 49
Alternative UPACC:
Q15427; Q5SZ63
Background:
Splicing factor 3B subunit 4 (SF3B4), also known as Pre-mRNA-splicing factor SF3b 49 kDa subunit or Spliceosome-associated protein 49, plays a crucial role in pre-mRNA splicing. It is a component of the SF3B complex, essential for the 'A' complex assembly and U2 snRNP's stable binding to the branchpoint sequence in pre-mRNA. SF3B4's involvement extends to the assembly of the 'E' complex and the splicing of U12-type introns, highlighting its multifaceted role in RNA processing.
Therapeutic significance:
SF3B4's mutation is linked to Acrofacial dysostosis 1, Nager type, characterized by craniofacial and limb malformations. Understanding the role of SF3B4 could open doors to potential therapeutic strategies for this genetic disorder.